BioSpace News Archive

Business

Corteva Agriscience Reports Third Quarter 2019 Results – Delivers Earnings Improvement Over Prior Year

GAAP earnings per share (EPS) from continuing operations was a loss of $(0.69) for the third quarter and operating EPS1 was a loss of $(0.39) – both improved compared to prior year.

October 31, 2019
·
18 min read
Deals

Corteva Announces Plans to Expand Global Spinosyns Capacity

Investment in Michigan Facility Targets Future Growth for High-Demand Natural Insecticide Technology

October 31, 2019
·
7 min read
Drug Development

ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

ObsEva SA announced that the U.S. Food and Drug Administration has allowed the Company to begin enrolling patients in IMPLANT 3, the U.S pivotal Phase 3 clinical trial of nolasiban in women undergoing embryo transfer following in-vitro fertilization.

October 31, 2019
·
5 min read